![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » TransGenic Applies for Urinary-Based Cancer Technology Patent
TransGenic Applies for Urinary-Based Cancer Technology Patent
January 31, 2005
TransGenic has applied for a patent for its proprietary cancer diagnostic technology currently under development. With the aid of Kogakuin University and Kyushu University, the company has developed an innovative technology that measures diacetyl spermine in urine to detect cancer.
Japan Corporate News
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct